| Objective Concurrent chemoradiotherapy is a standard treatment for malignant tumors, which can improve tumor control rates. However, factors such as treatment, tumor-related, and host factors can increase the risk of fungal infections in patients, affecting their prognosis. Currently, the combined use of serological markers, molecular diagnostic techniques, and emerging host immune indicators offers a new perspective for early prediction of fungal infections after concurrent chemoradiotherapy for malignant tumors. However, the sensitivity and specificity of single markers are insufficient, and there is an urgent need to integrate susceptibility factors to construct stratified early warning models. Systematically analyzing the susceptibility factors related to fungal infections after concurrent chemoradiotherapy for malignant tumors and integrating multi-dimensional fungal infection markers to build a dynamic prediction system is crucial for improving early warning efficiency, guiding treatment, and enhancing patient outcomes. This study reviews the progress in predicting susceptibility factors and markers related to fungal infections after concurrent chemoradiotherapy for malignant tumors, aiming to provide a basis for clinical treatment. |
